Targeted small molecule strategy against collagen α-3(iv) for anti-gbm disease

Overview

This research addresses Goodpasture syndrome, an orphan autoimmune disease in which autoantibodies target the collagen alpha-3(IV) chain, triggering inflammation and destruction of basement membranes in the kidneys and lungs. The proposed solution is a targeted small molecule strategy that interferes with the binding of these autoantibodies to collagen alpha-3(IV), potentially halting the immune cascade while allowing normal immune function to continue. The approach offers specificity, enhanced efficacy, direct disease intervention, and reduced side effects compared to broad immunosuppressive treatments.

Technical specifications

• Target identification: The epitope region of collagen alpha-3(IV) between amino acids 1427–1444 was selected as the binding site recognized by Goodpasture antibodies
• Library screening: Approximately 15,000 natural molecules from the MolPort library were assessed for binding affinity to the target
• Molecular docking and simulation: Top five bound complexes were identified and evaluated through long-term molecular dynamics simulations and free binding energy calculations
• Protein-protein docking validation: Docking studies with IgG1 antibody in the presence and absence of small molecules demonstrated that the small molecules decreased complex stability and efficiently blocked the immune response
• Future therapeutic modalities: Antisense oligonucleotides (ASOs) and monoclonal antibodies are also being designed to modulate or inhibit the collagen alpha-3(IV) pathway
• Planned in-vitro validation: Further testing against HEK-293, Pulmonary A549, and Jurkat cell lines

Technology readiness level

The research is currently at an early stage, with preliminary in-silico work completed including molecular docking, molecular dynamics simulations, and protein-protein docking validation. The next phase involves in-vitro wet lab studies to confirm the computational findings, with an estimated timeline of approximately six months. The lab is actively seeking partnership support for wet lab studies and funding for key personnel to advance validation. Complementary approaches using ASOs and monoclonal antibodies are also in the design stage.